Yichang IPO aims to woo choosy investors

The Chinese drug maker hopes to convince investors who have been highly selective in healthcare assets this year.

Chinese drug manufacturer Yichang HEC Changjiang Pharmaceutical launched an initial public offering in Hong Kong on Monday at a time investors are highly selective in taking on healthcare-related assets  

A termsheet seen by FinanceAsia shows the company is selling 90 1 million shares, or 20% of its enlarged share capital, at an indicative price range of HK$13 70-HK$18 50 per share at the base size There is a standard 15% greenshoe option

At this range, the company is valued at 13 6x-18 4x consensus analyst earnings estimates for next year on a pre-shoe basis, or 14 0x-19 0x on a post-shoe basis

The deal was launched as China’s pharmaceuticals sector faces pressure following the

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222